-
公开(公告)号:US11820774B2
公开(公告)日:2023-11-21
申请号:US17154761
申请日:2021-01-21
Inventor: Benjamin E. Blass , Daniel J. Canney , Kevin M. Blattner
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
-
公开(公告)号:US11547776B2
公开(公告)日:2023-01-10
申请号:US16608381
申请日:2018-04-26
Inventor: Azadeh Timnak , Peter I. Lelkes , Yah-el H. Har-el
Abstract: The present invention provides porous biomimetic scaffolds and methods for making the same. The scaffolds have graded pore sizes for enhanced cell penetration. The scaffolds are useful for wound regeneration by facilitating cell penetration into the scaffold interior and due to their inherent immunomodulatory effects. The scaffolds have tissue modeling specification by mimicking the inherent stratified structure of certain tissues.
-
公开(公告)号:US20230001016A1
公开(公告)日:2023-01-05
申请号:US17727438
申请日:2022-04-22
Inventor: Kamel Khalili , Wenhui Hu , Hassen Wollebo
IPC: A61K48/00 , C12N9/22 , C12N15/63 , C12N15/113
Abstract: The present invention includes methods and compositions for elimination of polyomaviruses, such as John Cunningham Virus (JVC), from host cells, and the treatment of polyomavirus related diseases, such as progressive multifocal leukoencephalopathy (PML). The compositions include isolated nucleic acid sequences comprising an CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a polyomavirus.
-
公开(公告)号:US11491207B2
公开(公告)日:2022-11-08
申请号:US16397823
申请日:2019-04-29
Applicant: Excision BioTherapeutics, Inc. , Temple University of the Commonwealth System of Higher Education
Inventor: Kamel Khalili , Thomas Malcolm , Kenneth I. Kohn
IPC: A61K38/46 , C12Q1/70 , C12N15/10 , C12N15/00 , A61P31/20 , A61K39/395 , C07K16/28 , C12N15/11 , A61K48/00 , A61K39/00
Abstract: A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.6, CasX, or argonaute protein, which target at least one nucleotide sequence of the JCV genome.
-
公开(公告)号:US20220313795A1
公开(公告)日:2022-10-06
申请号:US17329137
申请日:2021-05-24
Inventor: Kamel Khalili , Wenhui Hu
Abstract: A method of preventing transmission of a retrovirus from a mother to her offspring, by administering to the mother a therapeutically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and the two or more different multiplex gRNAs, wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, eradicating the HIV-1 proviral DNA from the host cell, and preventing transmission of the proviral DNA to the offspring.
-
公开(公告)号:US20220306596A1
公开(公告)日:2022-09-29
申请号:US17517166
申请日:2021-11-02
Inventor: Daniel J. Canney , Benjamin E. Blass , Rong Gao , Magid Abou-Gharbia
IPC: C07D307/33 , C07D307/94 , C07D405/06 , C07D405/12 , C07D307/28 , C07D405/14
Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
-
公开(公告)号:US20220227846A1
公开(公告)日:2022-07-21
申请号:US17579952
申请日:2022-01-20
Applicant: Temple University-of The Commonwealth System of Higher Education , LANKENAU INSTITUTE OF MEDICAL RESEARCH
Inventor: Cagla Tukel Wilson , Scott Dessain
Abstract: The present invention features compositions comprising an anti-amyloid antibody and methods of treating microbial infection and treating or preventing microbial biofilms using the composition.
-
公开(公告)号:US11387520B2
公开(公告)日:2022-07-12
申请号:US16340735
申请日:2017-10-09
Inventor: Stephanie Wunder , Mike Zdilla , Parameswara Rao Chinnam
IPC: H01M50/446 , H01M50/403 , H01M10/0525 , C04B41/00 , C04B41/48 , C04B41/50 , C04B41/52 , C04B41/89
Abstract: The invention provides a novel ceramic-metal oxide-polymer composite material. A functionalized metal oxide nanolayer coating can be bonded between LICGCs and polymers/oligomers, which protects the LICGC from corrosion, has a low interfacial resistance to Li+ migration, and can be a SIC. Hybrid ceramic-polymer electrolytes were formed by engineering the interface between a LICGC and a polymer, polyethylene oxide (PEO), by sputter coating a 200 nm thick SiO2 layer onto a lithium ion conducting glass ceramic (LICGC) and silanating the SiO2 with a functionalized PEG in the presence of LiTFSI. A low interfacial resistance (Rinterfacial) was measured, the same as that obtained for a SiO2 interface soaked with liquid tetraglyme/LiTFSI. The pegylated SiO2 interface (unlike the tetraglyme/LiTFSI interface) protected the LICGC from corrosion by Li0 metal. The (PEG-LiTFSI)—SiO2-LICGC could be bonded with polyethylene oxide/LiTFSI. This procedure provides a general method to bond other LICGCs to PEO-based polymers, and to incorporate other functionalities such as single ion conductivity into the interface via the incorporation of coupling agents with pendant anions.
-
公开(公告)号:US20220211804A1
公开(公告)日:2022-07-07
申请号:US17392024
申请日:2021-08-02
Inventor: Peter I. Lelkes , Yah-el H. Har-el , Cezary Marcinkiewicz , Philip Lazarovici , Sogol Moaiyed Baharlou , Jonathan A. Gerstenhaber
IPC: A61K38/16 , A61L27/18 , A61L27/54 , A61L26/00 , A61L15/32 , A61L15/44 , A61L27/22 , A61L15/26 , A61P17/02 , A61L27/52
Abstract: Compositions and methods for the promotion of wound healing and tissue regeneration are described. The compositions and methods make use of water-soluble soy protein isolates (WSsoy), Fraction 5, Fraction 9, and/or bioactive peptide components of soy protein isolates. The invention also relates to the unexpected discovery that purified WSsoy forms gel-like matrices when suspended within certain concentration ranges in an aqueous environment. The compositions of the invention comprising WSsoy promote natural healing and have a low risk profile.
-
公开(公告)号:US11325883B2
公开(公告)日:2022-05-10
申请号:US16764424
申请日:2018-11-20
Inventor: Edward G. Melenski , Wayne E. Childers , Marlene A. Jacobson , Magid A. Abou-Gharbia
IPC: C07C225/16 , A61K31/138 , A61P3/00 , C07C49/255 , A61P31/10
Abstract: Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gaucher's disease, and any disease or condition involving lysosomal storage dysfunction.
-
-
-
-
-
-
-
-
-